Two years ago, when 68-year-old Lars Nilsson relapsed after first-line treatment for chronic lymphocytic leukemia in Stockholm, his options were limited. Today, thanks to a groundbreaking trial presented at the European Hematology Association 2026 Congress, patients like him may have a far brighter outlook. Dr. Matthew Davids of Dana-Farber Cancer Institute unveiled interim results from the phase 3 BRUIN CLL-322 trial, showing that a fixed-duration triplet therapy—pirtobrutinib, venetoclax, and rituximab—delivers a dramatic leap in progression-free survival for those with relapsed or refractory CLL. This isn’t just incremental progress; it’s a potential redefinition of standard care.
For nearly a decade, the go-to second-line treatment has been venetoclax plus rituximab—a powerful but imperfect doublet. While effective, many patients eventually progress, especially those with high-risk features like TP53 aberrations or resistance to covalent BTK inhibitors such as ibrutinib. The BRUIN trial tested whether adding pirtobrutinib, a noncovalent BTK inhibitor approved by the FDA in 2025, could deepen and prolong responses. The answer, after analyzing data from 639 patients across multiple centers, was a resounding yes.
At the two-year mark, 86.9% of patients on the triplet therapy were alive and free of disease progression, compared to 71.8% on the doublet—translating to a 45% reduction in the risk of worsening disease or death. Even more encouraging: 86% of those on the triplet achieved undetectable minimal residual disease (MRD) in peripheral blood, a strong predictor of long-term remission, versus just 61% on the doublet. These benefits held across all subgroups, including those with prior BTK inhibitor resistance and TP53 mutations—historically among the hardest to treat.
Critically, the added efficacy came without a steep price in safety. Pirtobrutinib, known for its high selectivity and tolerability, did not significantly increase side effects when combined with the standard regimen. "Patients are getting this added progression-free survival benefit without much added toxicity," said Dr. Davids, emphasizing that even older patients with comorbidities could stand to gain. This balance of potency and safety makes the triplet a compelling candidate for broad adoption.
While overall survival data are still maturing, the trajectory is clear: fixed-duration, deeply effective therapy is within reach. For patients facing the anxiety of relapse, the prospect of a time-limited treatment that delivers lasting remission—without the burden of indefinite therapy—is transformative. As the medical community weighs these results, one thing is certain: the future of CLL care is looking far more hopeful.